Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|February 1, 2016
- Pharmaceutical Technology-02-02-2016
- Volume 40
- Issue 2
Ultra-High Shear Mixer
The Ross X-Series is a clean-in-place (CIP) ready ultra-high shear mixer for inline emulsification, particle size reduction, and homogenization.
The Ross X-Series is a clean-in-place (CIP) ready ultra-high shear mixer for inline emulsification, particle size reduction, and homogenization. It features a patented rotor/stator that runs at speeds more than 11,000 ft/min and forces product through concentric rows of intermeshing teeth. The combination of high fluid velocity and close tolerances between interlocking channels in the rotor/stator subjects the product to mechanical and hydraulic shear in a single pass. CIP-ready models are driven by a washdown-duty motor. All wetted parts are type 316 stainless steel machined to 32 Ra finish. The mix chamber, rated for 150 psig at 250 °F, includes tri-clamp inlet/outlet connections, and can be supplied with a heating/cooling jacket. It is designed for thorough cleaning and disinfection, with no dead zones where product can collect. The X-Series is equipped with a heavy-duty bearing assembly that comprises an oil sump with cooler and circulation pump for use in continuous operations.
www.mixers.com
Articles in this issue
over 10 years ago
Preventing Film Coating Problems by Designover 10 years ago
Going Small to Achieve Commercial-Scale Successover 10 years ago
Innovating for Innovationover 10 years ago
Faster, Cheaper, and Greenerover 10 years ago
Macro Mattersover 10 years ago
Innovative Therapies Require Modern Manufacturing Systemsover 10 years ago
Creating Robust CAPA Systemsover 10 years ago
Measurement Uncertainty without the Mathover 10 years ago
Pharmaceutical Technology, February 2016 Issue (PDF)over 10 years ago
Crossflow Filtration System for Process DevelopmentRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.